GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 21, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 21, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- August 2025 (date) — Reporting period
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically reporting on transactions in its own shares during the month of August 2025.
Who is acting as GSK's stockbroker for these transactions?
GSK is acting through its corporate stockbroker, Merrill Lynch International.
What type of shares did GSK purchase?
GSK purchased its own ordinary shares of 31¼ pence each.
Does the filing specify the number of shares purchased?
No, the filing states that GSK has purchased 'the following number of the Company's ordinary shares' but the specific number is not detailed in the provided text.
What is the principal executive office address for GSK plc?
The principal executive office address for GSK plc is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 2,918 words · 12 min read · ~10 pages · Grade level 3.5 · Accepted 2025-08-21 06:27:12
Filing Documents
- a1606w.htm (6-K) — 4883KB
- 0001654954-25-009874.txt ( ) — 4885KB
From the Filing
IN OWN SHARES a1606w   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   20 August 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   214,694   Lowest price paid per share (GBp):   1,450.50p   Highest price paid per share (GBp):   1,491.50p   Volume-weighted average price paid per share (GBp):   1,476.50p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 24,790,338 ordinary shares.   Following the above purchase, the Company will hold 242,924,721 ordinary shares in treasury and have 4,072,467,013 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,072,467,013. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.97 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:       GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:      20 August 2025   Investment firm:          Merrill Lynch International   Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   214,694   1,491.50p   1,450.50p   1,476.50p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   8,442   1,456.50    XLON   20-Aug-2025   08:00:17   0XL06A00000000008A13SN   10   1,454.50    XLON   20-Aug-2025   08:00:18   0XL06100000000008A13JV   10   1,454.50    XLON   20-Aug-2025   08:00:18   0XL06100000000008A13K0   10   1,454.50    XLON   20-Aug-2025   08:00:18   0XL06110000000008A13VF   10   1,454.50    XLON   20-Aug-2025   08:00:18   0XL06110000000008A13VG   10   1,454.50    XLON   20-Aug-2025   08:00:18   0XL06140000000008A13U7   10   1,454.50    XLON   20-Aug-2025   08:00:18   0XL06140000000008A13U8   10   1,454.50    XLON   20-Aug-2025   0